Scarica l'app Stockscreener
6.93
4.21%
0.28
Precedente Chiudi:
$6.65
Aprire:
$6.62
Volume 24 ore:
334.91K
Relative Volume:
2.86
Capitalizzazione di mercato:
$180.20M
Reddito:
$26.00M
Utile/perdita netta:
$-219.71M
Rapporto P/E:
-0.1392
EPS:
-49.8
Flusso di cassa netto:
$-51.37M
1 W Prestazione:
-8.82%
1M Prestazione:
-10.12%
6M Prestazione:
-27.36%
1 anno Prestazione:
-68.50%
Intervallo 1D:
$6.53
$7.00
Intervallo di 1 settimana:
$6.53
$7.73
Portata 52W:
$5.98
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Nome
Cartesian Therapeutics Inc
Settore
Industria
Telefono
301-348-8698
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Confronta RNAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
6.93 | 172.92M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-08-06 | Iniziato | TD Cowen | Buy |
| 2024-07-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Iniziato | Oppenheimer | Outperform |
| 2024-05-24 | Iniziato | Mizuho | Buy |
| 2024-04-23 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-23 | Iniziato | Leerink Partners | Outperform |
| 2023-08-18 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Reiterato | Needham | Buy |
| 2022-06-06 | Iniziato | SVB Leerink | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-01-26 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-10-01 | Downgrade | Mizuho | Buy → Neutral |
| 2020-10-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Downgrade | Stifel | Buy → Hold |
| 2020-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2020-01-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Iniziato | William Blair | Outperform |
| 2018-06-27 | Iniziato | Janney | Buy |
| 2017-03-30 | Reiterato | UBS | Buy |
Mostra tutto
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Why Cartesian Therapeutics Inc. (1S70) stock stays undervaluedJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
Weekly Earnings: What is the fair value estimate for Cartesian Therapeutics Inc 1S70 stock in 20252025 AllTime Highs & Reliable Volume Spike Trade Alerts - BỘ NỘI VỤ
What is the fair value estimate for Cartesian Therapeutics Inc. (1S70) stock in 2025Bond Market & Verified Momentum Stock Watchlist - Newser
Is Cartesian Therapeutics Inc. (1S70) stock a buy for dividend portfoliosEarnings Trend Report & Weekly Stock Breakout Alerts - Newser
Is Cartesian Therapeutics Inc. stock cheap at current valuationEarnings Growth Report & Real-Time Volume Analysis - Newser
Will Cartesian Therapeutics Inc. (1S70) stock outperform global peers2025 Big Picture & Technical Entry and Exit Alerts - Newser
What makes Cartesian Therapeutics Inc. (1S70) stock appealing to growth investorsQuarterly Profit Review & High Accuracy Buy Signal Tips - Newser
What MACD trends signal for Cartesian Therapeutics Inc. (1S70) stockWeekly Stock Recap & Weekly High Return Forecasts - Newser
Why Cartesian Therapeutics Inc. (1S70) stock remains stableEarnings Risk Report & Community Driven Trade Alerts - Newser
Cartesian Therapeutics, Inc. (RNAC) 7.5% in After-hours: Amid Routine Trading Conditions - Stocks Telegraph
Is Cartesian Therapeutics Inc. stock in correction or buying zoneJuly 2025 Update & Accurate Intraday Trade Tips - moha.gov.vn
Free cash flow per share of Cartesian Therapeutics, Inc. – MUN:1S70 - TradingView
Book value per share of Cartesian Therapeutics, Inc. – MUN:1S70 - TradingView
Is Umiya Tubes Limited Stock Risky in the Current Market EnvironmentInsider Selling Patterns & High Return Capital Gains - earlytimes.in
Will Cartesian Therapeutics Inc. stock deliver better than expected guidance - BỘ NỘI VỤ
Automated Systems Holdings Limited Announces Change in Share Registrar - The Globe and Mail
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $38.00 - Defense World
Will Cartesian Therapeutics Inc. (1S70) stock outperform energy sector in 2025July 2025 Levels & Weekly High Conviction Ideas - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock attract long term capital inflowsBear Alert & Daily Price Action Insights - newser.com
Is Cartesian Therapeutics Inc. stock a defensive play in 2025July 2025 Snapshot & Target Return Focused Picks - newser.com
How Cartesian Therapeutics Inc. (1S70) stock trades in high volatilityTrade Analysis Report & Risk Managed Trade Strategies - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock recover faster than industryWeekly Stock Analysis & Low Risk Growth Stock Ideas - newser.com
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Is Cartesian Therapeutics Inc. a candidate for recovery playWeekly Profit Summary & Consistent Return Investment Signals - newser.com
[Form 4] Cartesian Therapeutics, Inc. Insider Trading Activity - Stock Titan
H.C. Wainwright lowers Cartesian Therapeutics stock price target to $30 from $40 By Investing.com - Investing.com South Africa
Dir Singer Gifts 20,000 Of Cartesian Therapeutics Inc [RNAC] - TradingView
Ranking Cartesian Therapeutics Inc. among high performing stocks via tools2025 Buyback Activity & Fast Gain Stock Trading Tips - newser.com
H.C. Wainwright lowers Cartesian Therapeutics stock price target to $30 from $40 - Investing.com Canada
What indicators show strength in Cartesian Therapeutics Inc.July 2025 Recap & AI Powered Buy and Sell Recommendations - newser.com
HC Wainwright & Co. Maintains Cartesian Therapeutics (RNAC) Buy Recommendation - Nasdaq
How Cartesian Therapeutics Inc. stock performs during Fed tightening cyclesQuarterly Portfolio Report & Entry and Exit Point Strategies - newser.com
HC Wainwright & Co. Lowers Price Target for RNAC Despite Maintai - GuruFocus
Cartesian Therapeutics (RNAC) Receives Lowered Price Target but Retains Buy Rating - GuruFocus
Is Cartesian Therapeutics Inc. stock supported by strong fundamentals2025 Biggest Moves & Step-by-Step Swing Trade Plans - newser.com
Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):